eMQT
- Company typePrivate
- Founded2018
- HeadquartersMilton Keynes, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
eMQT firmographics
Firmographics- Name
- eMQT
- Legal name
- Emerging Market Quality Trials (eMQT)
- Website
- https://emqt.org.uk
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
eMQT industry classification
Industry- Product category
- Clinical Trial Services
- NAICS
- Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
- akta.pro primary industry
- Site Network Operators & SMOs (HLAGACAA)
- akta.pro secondary industries
- Clinical Trial Site Operations & Study Coordination (HLAGACAE), Investigator & Site Training / GCP Support (HLAGACAF), Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK), Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)
Keywords
Where eMQT is headquartered
LocationHeadquarters
- HQ city
- Milton Keynes
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
eMQT business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Consultancy services: Fee-based advisory services for pharmaceutical and biotech clients across emerging markets.
- Project management and trial delivery: Professional/managed services for end-to-end clinical trial project delivery in emerging-market geographies.
- Biospecimen collection and management: Specialist managed-service offering for biospecimen collection, handling, and management.
- Alpha4Pharma licensing: Licensing royalties from the AI-powered Alpha4Pharma document automation platform co-developed with JE Consulting.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Quote-based / not publicly disclosed |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
eMQT product offering
Product offeringCore offering
eMQT enables pharmaceutical, biotech, diagnostics and MedTech sponsors to conduct clinical trials in emerging markets, particularly across Africa, by combining proprietary technology platforms (Alpha4Pharma AI document automation, ATOM site capability assessment, and INSIGHT learning management) with professional services spanning regulatory and strategy consultancy, full trial project management, and biospecimen collection and management. The integrated offering is targeted at sponsors and CROs that need an Africa-experienced partner to compress trial start-up timelines and operate compliantly in low- and middle-income African jurisdictions.
Product overview
eMQT (Emerging Markets Quality Trials) delivers a portfolio of three core technology platforms wrapped by a suite of professional services, all oriented to enable the pharmaceutical industry to access African patients and clinical trial sites. The technology stack centres on two Centre of Excellence Enablement platforms — INSIGHT (an online knowledge management / LMS delivering accredited ICH-GCP and clinical trial training to stakeholders including patients) and ATOM (a site capability assessment tool that records and analyses site attributes for gap analysis) — together with Alpha4Pharma, an AI document automation platform developed with Jean Edwards Consulting that uses NLP and machine learning to auto-generate regulatory submissions and integrates with ClinicalTrials.gov via its API. These three platforms underpin four professional service lines: Biospecimen Collection and Management (prospective and retrospective sample collection across Sub-Saharan Africa), Africa Strategy & Regulatory Navigation Consultancy, Project Management & Trial Delivery (end-to-end trial management), and a Technology Innovation practice housing Alpha4Pharma and other AI-driven solutions. Together, the integrated platform-plus-services architecture reduces clinical trial timelines and costs while expanding the inclusion of African sites and populations in global research.
Differentiator
Problem solved
Functional benefit
Brands
- ATOM: Assessment Tool for Overseas Markets — eMQT's proprietary site capability assessment tool used to record key site attributes (ethics timelines, equipment, IMP storage, etc.), support gap analysis and identify African Centres of Excellence for commercial clinical trials.
- INSIGHT
- Alpha4Pharma
Products and services
- Alpha4Pharma
Quantifiable outcome
- Targets the underrepresentation gap: people of African descent are 17% of world population but less than 3% of trial participants (as stated in source).
- +1 more outcomes
Companies that use eMQT
Customer profileSegments6 records
Ideal customer profiles3 records
eMQT technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability7 records
Feature3 records
eMQT partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- JE Consulting (Jean Edwards Consulting)coreJE Consulting co-developed the Alpha4Pharma AI document automation platform with eMQT. The partnership is foundational to eMQT's technology innovation offering and is highlighted as a flagship technology alliance.
- Breast Without Spot (BWS)coreBreast Without Spot is the implementation partner for eMQT's breast cancer screening clinical programme in Nigeria. Together they deliver breast cancer screening using eMQT's clinical research and capability-building infrastructure.
- Institute of Clinical ResearchminorThe Institute of Clinical Research is referenced in connection with key personnel (Tina Barton), supporting eMQT's positioning in the clinical research professional community.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
eMQT competitors and assessment
Company assessmentDirect peers
- PSI CRO: Privately held, mid-size CRO with strong emerging-markets presence and full-service trial delivery; comparable in size, ownership structure, and geographic specialisation to eMQT.
- George Clinical: Asia-Pacific and emerging-markets CRO offering scientific leadership, project management and site-network services — a closely comparable emerging-market CRO to eMQT, with overlapping sponsor targets.
- Clinipace Worldwide: Mid-size, technology-enabled CRO serving small and mid-sized biopharma across multiple geographies; comparable to eMQT in serving sponsors that tier-1 CROs underserve and in offering technology-augmented delivery.
- Cromos Pharma: Mid-size CRO explicitly focused on emerging-market and Eastern European clinical trial execution, with a meaningful Africa/Eastern Europe footprint — directly comparable to eMQT's emerging-market trial-delivery model.
- Novotech: Asia-Pacific-focused mid-size CRO with growing emerging-markets capabilities; comparable in offering sponsors access to under-represented populations in geographies that have historically been underserved by tier-1 CROs.
Broad incumbents
- Parexel International: Large global CRO with established emerging-market delivery and regulatory expertise; competes with eMQT for sponsor contracts and could easily absorb eMQT-like African delivery work as a subcontracted region.
- IQVIA: World's largest CRO with broad geographic coverage and substantial investments in AI-driven clinical operations; competes with eMQT for the same pharma sponsors on global trial programmes, particularly where African sites are added to existing protocols.
- Medidata Solutions (Dassault Systèmes): Leading clinical trial technology platform (Rave EDC, eCOA, Rave AI) used by most CROs and sponsors; comparable to the Alpha4Pharma/INSIGHT/ATOM layer of eMQT's stack as adjacent clinical-trial software infrastructure.
- Medpace: Profitable mid-to-large CRO with strong technology orientation; comparable in being tech-forward and full-service, but with much broader geographic reach and sponsor base than eMQT.
Emerging players
- TrialKit / ClinOne: Technology-focused clinical trial platform vendors serving decentralised and emerging-market trials; comparable to eMQT as tech-enabled trial-enablement players targeting similar sponsor pain points around document automation and site enablement.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
eMQT social profiles
Digital presenceeMQT compliance and trust
Trust signalCompliance3 records
eMQT financial estimates
Financial estimateRevenue estimate
Valuation estimate
eMQT leadership team
Management profileNumber of profiles
Profiles2 records
eMQT funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
eMQT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about eMQT
What does eMQT do?
eMQT enables pharmaceutical, biotech, diagnostics and MedTech sponsors to conduct clinical trials in emerging markets, particularly across Africa, by combining proprietary technology platforms (Alpha4Pharma AI document automation, ATOM site capability assessment, and INSIGHT learning management) with professional services spanning regulatory and strategy consultancy, full trial project management, and biospecimen collection and management. The integrated offering is targeted at sponsors and CROs that need an Africa-experienced partner to compress trial start-up timelines and operate compliantly in low- and middle-income African jurisdictions.
Is eMQT a public or private company?
eMQT is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was eMQT founded?
eMQT was founded in 2018. It employs 1 to 10 people.
Where is eMQT based?
eMQT is headquartered in Milton Keynes, United Kingdom, in the Europe region.
How does eMQT make money?
Four revenue lines are on record. Consultancy services are the primary driver. The others are project management and trial delivery, biospecimen collection and management and alpha4Pharma licensing.
Who are eMQT's main competitors?
Direct peers on record are PSI CRO, George Clinical, Clinipace Worldwide, Cromos Pharma and Novotech. Broad incumbents are Parexel International, IQVIA, Medidata Solutions (Dassault Systèmes) and Medpace. TrialKit / ClinOne is listed as an emerging player.
Does eMQT have an API?
Yes. Alpha4Pharma, eMQT's AI document automation platform, programmatically integrates with the ClinicalTrials.gov API to auto-populate registry fields from clinical protocol documents using advanced NLP and machine learning. Alpha4Pharma is also described as having 'the ability to integrate with external systems' and 'platform interoperability' for adoption across clinical trial stakeholders. No public developer portal or self-service documentation URL is provided; the API capability is described as partner-/enterprise-facing.
What industry is eMQT in?
eMQT's product category is Clinical Trial Services. Its primary akta.pro industry code is HLAGACAA, Site Network Operators & SMOs, with a secondary code of HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 5417 and its SIC code is 8731.